Wolfe Research downgraded Verona Pharma (VRNA) to Peer Perform from Outperform without a price target after Merck (MRK) announced it will acquire Verona for $10B or $107 per share.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma downgraded to Neutral from Buy at Roth Capital
- Verona Pharma Stock (VRNA) Soars 20% on $10B Merck Deal
- Verona Pharma downgraded to Neutral from Buy at BTIG
- Verona Pharma downgraded to Equal Weight from Overweight at Wells Fargo
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!